Core Insights - The company reported a revenue of 311,445,583.30 yuan for the first half of 2025, representing a year-on-year decline of 11.52% [2] - The net profit attributable to shareholders of the listed company was 37,557,144.18 yuan, showing a year-on-year decrease of 5.27% [2] Financial Performance - Revenue for the first half of 2025: 311.45 million yuan, down 11.52% year-on-year [2] - Net profit for the same period: 37.56 million yuan, down 5.27% year-on-year [2]

2025年8月15日，易明医药(002826.SZ)发布2025年半年度报告。截至2025年8月14日，共有1个机构投资 者披露持有易明医药A股股份，合计持股量达168.00万股，占易明医药总股本的0.88%。其中，机构投 资者包括中证乾元资本管理有限公司-中证乾元三号私募证券投资基金，机构投资者合计持股比例达 0.88%。相较于上一季度，机构持股比例合计上涨了0.13个百分点。 公募基金方面，本期较上一季未再披露的公募基金共计1个，即诺安多策略混合A。 外资态度来看，本期较上一季未再披露的外资机构即MORGAN STANLEY & CO. INTERNATIONAL PLC.。 ...

易明医药2025半年报 ...

Core Viewpoint - Yiming Pharmaceutical announced the approval of multiple proposals during the 26th meeting of its third board of directors on the evening of August 14 [2] Group 1 - The company held a board meeting to discuss and approve various proposals [2]

Group 1 - Tongda Power achieved a net profit of 42.64 million yuan in the first half of 2025, a year-on-year increase of 32.49% [1] - The company reported an operating income of 971 million yuan, up 22.07% year-on-year [1] - Basic earnings per share were 0.26 yuan [1] Group 2 - Hengshen New Materials reported a net loss of 36.70 million yuan in the first half of 2025, compared to a loss of 10.37 million yuan in the same period last year [2][3] - The company's operating income decreased by 24.84% to 1.22 billion yuan [2] Group 3 - Yiming Pharmaceutical's net profit was 37.56 million yuan, down 5.27% year-on-year [4] - The company experienced an 11.52% decline in operating income, totaling 311 million yuan [4] - Basic earnings per share were 0.20 yuan [4] Group 4 - Wangsu Technology achieved a net profit of 37.30 million yuan, a year-on-year increase of 25.33% [5] - The company's operating income was 2.35 billion yuan, up 2.19% year-on-year [5] - Basic earnings per share were 0.1524 yuan [5] Group 5 - Alloy Investment reported a net profit of 4.58 million yuan, a year-on-year increase of 44.12% [6] - The company achieved an operating income of 164 million yuan, up 73.46% year-on-year [6] - Basic earnings per share were 0.0119 yuan [6] Group 6 - Yifan Pharmaceutical's net profit was 30.40 million yuan, a year-on-year increase of 19.91% [8] - The company's operating income was 2.635 billion yuan, up 0.11% year-on-year [8] - Basic earnings per share were 0.25 yuan [8] Group 7 - Guoyao Yizhi reported a net profit of 66.60 million yuan, a year-on-year decrease of 10.43% [9] - The company's operating income was 36.797 billion yuan, down 2.62% year-on-year [9] - Basic earnings per share were 1.20 yuan [9] Group 8 - Hanjia Design expects a net profit of 15 to 16.5 million yuan, a year-on-year increase of 303.20% to 343.52% [10] - The company anticipates a net profit excluding non-recurring gains and losses of 14.5 to 17.5 million yuan, a year-on-year increase of 867.05% to 1067.13% [10] Group 9 - Gansu Energy Chemical announced the resumption of production at its Jinhe Coal Mine after passing safety inspections [16] Group 10 - Chuanjin Nuo reported a net profit of 177 million yuan, a year-on-year increase of 166.51% [18] - The company's operating income was 1.744 billion yuan, up 27.91% year-on-year [18] - Basic earnings per share were 0.6457 yuan [18] Group 11 - Yachuang Electronics achieved a net profit of 40.82 million yuan, a year-on-year increase of 1.47% [19] - The company's operating income was 2.847 billion yuan, up 125.74% year-on-year [19] - Basic earnings per share were 0.29 yuan [19] Group 12 - Yiheda reported a net profit of 282 million yuan, a year-on-year increase of 26.49% [14] - The company's operating income was 1.461 billion yuan, up 18.70% year-on-year [14] - Basic earnings per share were 0.44 yuan [14] Group 13 - Hatao Technology reported a net profit of 38 million yuan, a year-on-year increase of 233.08% [33] - The company's operating income was 1.475 billion yuan, up 1.12% year-on-year [33] - Basic earnings per share were 0.18 yuan [33] Group 14 - Anlu Technology announced that shareholders plan to reduce their holdings by no more than 3.25% of the company's shares [35] Group 15 - Baolidi reported a net profit of 63.81 million yuan, a year-on-year increase of 15.19% [36] - The company's operating income was 676 million yuan, up 1.47% year-on-year [36] - Basic earnings per share were 0.36 yuan [36] Group 16 - Harta Technology reported a net profit of 33.50 million yuan, a year-on-year increase of 55.61% [38] - The company's operating income was 335 million yuan, up 22.54% year-on-year [38] - Basic earnings per share were 0.0698 yuan [38] Group 17 - Huaxia Biological's controlling shareholder received a loan commitment of up to 250 million yuan from China Merchants Bank [58]

Core Viewpoint - The report highlights the financial performance and operational strategies of Tibet Aim Pharma Co., Ltd. for the first half of 2025, indicating a decline in revenue and net profit while emphasizing the company's focus on maintaining stability and enhancing core product market share amidst industry challenges [2][5][11]. Financial Performance - The company's operating revenue for the first half of 2025 was CNY 311.45 million, a decrease of 11.52% compared to CNY 351.98 million in the same period last year [2][11]. - The net profit attributable to shareholders was CNY 37.56 million, down 5.27% from CNY 39.65 million year-on-year [2][11]. - The net cash flow from operating activities increased by 35.39% to CNY 62.46 million, compared to CNY 46.13 million in the previous year [2][11]. - Total assets at the end of the reporting period reached CNY 1.01 billion, an increase of 8.50% from CNY 926.47 million at the end of the previous year [2][11]. Industry Context - The healthcare reform in China is focusing on building a sustainable medical security system, with a shift from "low price only" to "quality first, reasonable price" in drug procurement policies [5][6]. - The market for chronic disease medications is rapidly growing, particularly in grassroots healthcare settings, with significant increases in spending on cardiovascular and diabetes medications [5][6]. - The company is positioned to benefit from these trends by leveraging its product portfolio and focusing on innovative drug development [5][6]. Business Model and Product Overview - The company's main products are categorized into self-produced drugs and third-party cooperative drugs, with a focus on enhancing market share for core products [5][6][11]. - Key self-produced products include Miglitol tablets, which have a leading market share in the domestic market for Type 2 diabetes medications [8][10]. - The company has successfully participated in multiple rounds of national drug procurement, securing contracts across various provinces [8][10]. Operational Strategies - The company is implementing a "stabilization" strategy to maintain steady operations while enhancing the market presence of its core products [5][11]. - Marketing efforts are centered around target customers, utilizing a multi-channel approach to expand market share and create new profit growth points [6][11]. - Continuous improvements in production management and quality control are being prioritized to ensure product quality and operational efficiency [6][11].

智通财经APP讯，易明医药(002826.SZ)发布2025年半年度报告，报告期内，公司实现营业收入3.11亿 元，同比下降11.52%。实现归属于上市公司股东的净利润3755.71万元，同比下降5.27%。实现归属于上 市公司股东的扣除非经常性损益的净利润2502.22万元，同比增长102.33%。基本每股收益0.2元。 ...

| | | | | 要 | | | --- | --- | --- | --- | --- | --- | | 证券代码：002826 证券简称：易明医药 | | | 公告编号： | | | | 2025-055 | | | | | | | 西藏易明西雅医药科技股份有限公司 2025 年半年度报告摘要 | | | | | | | 一、重要提示 | | | | | | | 本半年度报告摘要来自半年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投 | | | | | | | 资者应当到证监会 | | | | | | | 指定媒体仔细阅读半年度报告全文。 | | | | | | | 所有董事均已出席了审议本报告的董事会会议。 | | | | | | | 非标准审计意见提示 | | | | | | | □适用 ?不适用 | | | | | | | 董事会审议的报告期利润分配预案或公积金转增股本预案 | | | | | | | □适用 | | | | | ?不适用 | | 公司计划不派发现金红利，不送红股，不以公积金转增股本。 | | | | | | | 董事会决议通过的本报告期优先股利润分配预案 | ...

Group 1 - The third meeting of the board of directors of Tibet Yiming Xiya Pharmaceutical Technology Co., Ltd. was held on August 13, 2025, with all 7 directors present, confirming compliance with relevant laws and regulations [1] - The board unanimously approved the 2025 semi-annual report and its summary, affirming that the report accurately reflects the company's actual situation without any false statements or omissions [2] - The company plans to apply for a comprehensive credit limit of up to RMB 100 million from CITIC Bank's Lhasa branch, with an exposure limit of RMB 80 million and a two-year credit term [2]

西藏易明西雅医药科技股份有限公司 二〇二五年半年度财务报告 （未经审计） 西藏易明西雅医药科技股份有限公司 财务报表及附注 （2025 年 06 月 30 日止） 目 录 页 次 财务报表 1-18 合并资产负债表和公司资产负债表 合并利润表和公司利润表 合并现金流量表和公司现金流量表 合并所有者权益变动表和公司所有者权益变动表 财务报表附注 19-104 1、合并资产负债表 编制单位：西藏易明西雅医药科技股份有限公司 2025 年 06 月 30 日 单位：元 | 项目 | 期末余额 | 期初余额 | | --- | --- | --- | | 流动资产： | | | | 货币资金 | 265,948,740.21 | 427,398,137.38 | | 结算备付金 | | | | 拆出资金 | | | | 交易性金融资产 | 250,000,000.00 | | | 衍生金融资产 | | | | 应收票据 | 91,592.00 | 12,866,464.70 | | 应收账款 | 44,865,565.84 | 39,508,143.20 | | 应收款项融资 | | | | 预付款项 | 2,903 ...